US Stock MarketDetailed Quotes
BRTX Biorestorative Therapies
- 1.450
- -0.010-0.68%
Close Dec 13 16:00 ET
- 1.450
- 0.0000.00%
Post 20:02 ET
10.03MMarket Cap-1.01P/E (TTM)
1.460High1.440Low4.91KVolume1.450Open1.460Pre Close7.06KTurnover0.11%Turnover RatioLossP/E (Static)6.92MShares3.67052wk High1.01P/B6.38MFloat Cap1.03052wk Low--Dividend TTM4.40MShs Float8.900Historical High--Div YieldTTM1.37%Amplitude1.030Historical Low1.437Avg Price1Lot Size
Biorestorative Therapies Stock Forum
Sign in to post a comment
$Biorestorative Therapies (BRTX.US)$ Reuters
Just
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting Thermostem® Metabolic Disease Program
Just
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting Thermostem® Metabolic Disease Program
2
$Biorestorative Therapies (BRTX.US)$
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
Thursday, 5th December at 6:45 am
– Covers cGMP manufacturing processes –
– Expected to provide protection until April 29, 2040 –
MELVILLE, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused on stem...
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
Thursday, 5th December at 6:45 am
– Covers cGMP manufacturing processes –
– Expected to provide protection until April 29, 2040 –
MELVILLE, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused on stem...
1
$Biorestorative Therapies (BRTX.US)$
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
5 minutes ago, 4:00 AM PST
Via GlobeNewswire
– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints –
– Patient reported efficacy outcomes show a material decrease in pain and increase in function –
– If positive trends continue, Company confident that the Phase 2 trial will meet its Primary and Secondary end points -
...
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
5 minutes ago, 4:00 AM PST
Via GlobeNewswire
– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints –
– Patient reported efficacy outcomes show a material decrease in pain and increase in function –
– If positive trends continue, Company confident that the Phase 2 trial will meet its Primary and Secondary end points -
...
1
$Biorestorative Therapies (BRTX.US)$
MELVILLE, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it has received a provisional license from the New York State Department of Health (“NYSDOH”) for the pro...
MELVILLE, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it has received a provisional license from the New York State Department of Health (“NYSDOH”) for the pro...
$Biorestorative Therapies (BRTX.US)$ Reuters· just
BioRestorative Therapies Receives Expanded Tissue License From New York State Department of Health
BioRestorative Therapies Receives Expanded Tissue License From New York State Department of Health
2
$Biorestorative Therapies (BRTX.US)$
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
BioRestorative Therapies has received a Notice of Allowance from the Israel Patent Office for its ThermoStem® technology platform. This marks the 14th international patent outside the U.S. for this technology. The patent covers brown adipose derived stem cell (BADSC) aggregates, encapsulation systems, and treatment methods. The company believes ThermoStem®-based BA...
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
BioRestorative Therapies has received a Notice of Allowance from the Israel Patent Office for its ThermoStem® technology platform. This marks the 14th international patent outside the U.S. for this technology. The patent covers brown adipose derived stem cell (BADSC) aggregates, encapsulation systems, and treatment methods. The company believes ThermoStem®-based BA...
1
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program.
BioRestorative Therapies, Inc. (BioRestorative or BRTX), a company specializing in stem cell-based therapies, has announced that it received a notice of allowance from the Japanese Patent Office for patent application No. 2021-564135. This patent pertains to the com...
BioRestorative Therapies, Inc. (BioRestorative or BRTX), a company specializing in stem cell-based therapies, has announced that it received a notice of allowance from the Japanese Patent Office for patent application No. 2021-564135. This patent pertains to the com...
$Biorestorative Therapies (BRTX.US)$ Reuters · 1 min ago BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of Thermostem® Metabolic Disease Program
1
2
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Anthony tan81 : looks like a brutal dip![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP Anthony tan81 : Yeah not a lot of volume! Remember PM can be very hard to trade! You’re not seeing true market interest or liquidity. You only have a fraction of traders who are or even can trade!